After a unanimous panel vote, will Spark's novel gene therapy be a 1 million drug

    Share on Google+        
After a unanimous panel vote, will Spark's novel gene therapy be a 1 million drug
Click on the image
If the panel votes yes and the FDA follows its recommendation, Luxturna would become the first therapy meant to replace or repair a defective gene approved in the U.S. Spark hasn't disclosed pricing, but analysts estimate Luxturna could cost $1 million or more per patient, a price that might force payers and insurers to rethink their coverage and reimbursement models.

About Us
posted-today.org shows the most important world news of the day, under the editorial criteria of their impact on Internet and social networks.
Contact
Do you have any suggestion? Contact us.

    Share on Google+        

We might need you!
Investors and business angels continue reading, please: posted-today.org is a very innovative project which has just started. We can steadily grow in visits and content and become leaders of the digital press in an ETA of 10 years. This curve of success could be considerably improved having more resources. If you stand out for your vision of the future, maybe you can help us, or the other way round.
Technology
This is not just buzzing words: posted-today.org is an example of what you get when applying state-of-the-art technologies, such as Big Data, Content Curation, Natural Language Processing (NLP), NoSQL, Cloud Computing, ...